Bluetrain

Bluetrain Therapeutics is a biotechnology company focused on developing novel cancer therapies by targeting nucleolar stress and ribosome biogenesis. The company leverages a proprietary platform to identify and exploit vulnerabilities in the nucleolus, a key organelle involved in protein synthesis that is often dysregulated in cancer cells. By inducing nucleolar stress, Bluetrain aims to trigger selective apoptosis in tumor cells while sparing healthy tissue. Headquartered in Cambridge, Massachusetts, the company is backed by leading life science investors and focuses on precision oncology through small molecule intervention.